MY166634A - A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent - Google Patents

A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

Info

Publication number
MY166634A
MY166634A MYPI2012001764A MYPI2012001764A MY166634A MY 166634 A MY166634 A MY 166634A MY PI2012001764 A MYPI2012001764 A MY PI2012001764A MY PI2012001764 A MYPI2012001764 A MY PI2012001764A MY 166634 A MY166634 A MY 166634A
Authority
MY
Malaysia
Prior art keywords
compound
treating cancer
active agent
chymotrypsinogen
trypsinogen
Prior art date
Application number
MYPI2012001764A
Inventor
Julian Norman Kenyon
Paul Rodney Clayton
David Tosh
Fernando Felquer
Ralf Brandt
Original Assignee
Propanc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905147A external-priority patent/AU2009905147A0/en
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Publication of MY166634A publication Critical patent/MY166634A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE PRESENT INVENTION GENERALLY RELATES TO PHARMACEUTICAL COMPOSITIONS CONTAINING A PROTEASE PROENZYME AND USE THEREOF FOR TREATING CANCER. THE PHARMACEUTICAL COMPOSITIONS ARE DIRECTED TO COMPOSITIONS COMPRISING A PROTEASE PROENZYME AND AN ACTIVE AGENT, THE COMPOSITION BEING CAPABLE OF PROVIDING A MULTI-FUNCTIONAL APPROACH FOR TREATING CANCER. THE PHARMACEUTICAL COMPOSITIONS ARE ALSO DIRECTED TO COMPOSITIONS COMPRISING A FIRST AND A SECOND PROTEASE PROENZYME CAPABLE OF ACTIVATION AT OR NEAR A SURFACE OF A TUMOUR CELL TO ENHANCE CELL-TO-CELL ADHESION OF TUMOUR CELLS, EFFECT PROTEOLYSIS OF TUMOUR CELLS, OR INDUCE TUMOUR CELL APOPTOSIS, DIFFERENTIATION OR IMMUNORECOGNITION, WHEREIN THE FIRST PROTEASE PROENZYME IS CHYMOTRYPSINOGEN AND THE SECOND PROTEASE PROENZYME IS TRYPSINOGEN. THE PHARMACEUTICAL COMPOSITIONS ARE ALSO DIRECTED TO COMPOSITIONS COMPRISING A FIRST AND SECOND ACTIVE AGENT EACH CAPABLE OF INDUCING INTRACELLULAR ACTIVITY IN TUMOUR CELLS.
MYPI2012001764A 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent MY166634A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2009905147A AU2009905147A0 (en) 2009-10-22 Pharmaceutical Compositions

Publications (1)

Publication Number Publication Date
MY166634A true MY166634A (en) 2018-07-17

Family

ID=64292244

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012001764A MY166634A (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

Country Status (1)

Country Link
MY (1) MY166634A (en)

Similar Documents

Publication Publication Date Title
MX355971B (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent.
MX2014008640A (en) Pharmaceutical compositions and methods.
EA201390756A1 (en) MODULATING NK-CELL TREATMENTS AND METHODS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
TR201907783T4 (en) Benzosulfonamide derivatives, compositions and their use in the prevention of cancer cell metastasis.
MX2019008803A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof.
EA201390031A1 (en) MODIFICATORS OF ARYL-HYDROGEN-HYDROGEN RECEPTOR (AhR) AS NEW ANTI-TREATMENT THERAPEUTIC TOOLS
NZ703148A (en) Modified factor x polypeptides and uses thereof
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MX2009011970A (en) Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof.
CL2011001863A1 (en) Compounds derived from phenylaminopyrimidines, anaplastic lymphoma kinase inhibitors; pharmaceutical composition; pharmacological combination; and its use in the treatment of proliferative disorders such as lymphoma, osteosarcoma, melanoma or breast, renal and prostate tumor, among others (divisional application 3552-07).
CL2013001138A1 (en) Composition comprising bispecific cd19xcd3 antibody to treat tumor mass of lymph node tissue and / or extranodal lymphoma caused by diffuse large cell lymphoma b (lbdcg); pharmaceutical kit; Use of the composition.
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
MX2012014080A (en) Uses and compositions for treatment of hidradenitis suppurativa (hs).
HK1106534A1 (en) Proteasome inhibitors and methods of using the same
MX2011006685A (en) Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
BR112013003823A2 (en) therapeutic peptide-polymer conjugates, particles, compositions, and related methods
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2008125116A3 (en) Upar inhibition
BR112014011254A2 (en) 2-thiopyrimidinones
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
MY166634A (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
WO2009126804A3 (en) Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
WO2014062811A3 (en) METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2